Q32 Bio sells asset for $12M plus up to $592M, eyes mid-2026 bempikibart data
Q32 Bio sold ADX-097 to Akebia for $12 million upfront plus up to $592 million in milestones and royalties, refocusing on bempikibart for alopecia areata. Part A of the SIGNAL-AA Phase IIa showed statistically significant SALT reductions and durability through week 55, and Part B with 33 patients expects mid-2026 top-line data.
1. Asset Sale Sharpens Strategic Focus
Q32 Bio completed the divestiture of its non-core asset ADX-097 to Akebia for $12 million upfront and potential total consideration of up to $592 million plus royalties. The transaction allows Q32 to concentrate resources and capital exclusively on advancing its lead candidate bempikibart in alopecia areata.
2. Part A SIGNAL-AA Efficacy and Durability
In Part A of the SIGNAL-AA Phase IIa study, bempikibart delivered a statistically significant reduction in SALT scores, with some patients maintaining and even regaining hair through approximately week 55 after dosing cessation. Management highlighted a favorable safety profile compared with JAK inhibitors and responses in hard-to-treat patients with longer disease duration.
3. Part B Trial Design and Expectations
Part B has enrolled 33 patients using a 200 mg regimen, exceeding the original goal of 20 evaluable subjects. The study features central eligibility review, a two-year episode duration limit and a 36-week dosing period followed by a 16-week follow-up, with top-line results anticipated by mid-2026 and remission data to week 52 later in the year.
4. Commercial and Milestone Outlook
Q32 Bio targets a mid-20% SALT 20 response rate as a Phase III gating point, aiming to position bempikibart ahead of JAK inhibitors in the alopecia areata market. The company could unlock up to $592 million in milestone payments based on clinical and regulatory achievements, supporting its broader pipeline ambitions.